Participated · Equity · Jun 2026

Portal builds a proprietary mechanoporation-based platform to enable efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across diverse cell types and workflows. The company targets applications across novel drug discovery workflows, multi-perturbation AI data generation, and next-generation cell therapies, and integrates with high-throughput robotics and GMP manufacturing systems. Portal reports commercial traction with more than 100 customer sites, including public collaborations or use by Microsoft, Merck, AbbVie, Mass General Brigham, the Ragon Institute, and Purdue University. Use cases highlighted include high-throughput, physiologically relevant screening, generation of model-training biological data, and same-day circRNA-based multifunctional CAR-T production at the point of care. DARPA has expanded an initial $8M contract and is supporting commercialization through its EEI program, underscoring validation for Portal's point-of-care cell therapy manufacturing efforts. The company states it has achieved meaningful commercial revenue and technical validation from large pharma and academic partners.

Participated · Seed · Jul 2024

SoundHealth develops personalized, AI-enabled, non-invasive medical and wellness devices targeting breathing and sleep disorders. Its flagship FDA-cleared Sonu band has delivered more than 500,000 acoustic resonance treatment sessions for users ages 12 and up and is described as a leading steroid alternative for congestion due to allergic and non-allergic rhinitis. The company has built a craniofacial anatomical dataset used to personalize treatments and to underpin its Spatial Sleep product, which the company says is the world’s first clinically proven personalized sleep wellness device and has been shown to help users fall asleep faster and sleep longer. SoundHealth is recommended by more than 1,000 medical and dental professionals nationwide. Following the Series A, the company has $12.25 million in total funding to date to support further growth and commercialization.

Participated · Seed · Mar 2024

Founded in May 2020 at EPFL in Lausanne, Switzerland, Alithea Genomics builds technologies that dramatically lower the cost and increase the throughput of RNA sequencing. Its flagship BRB-seq and DRUG-seq platforms can prepare up to 1,536 RNA samples in a single tube, with DRUG-seq eliminating the need for RNA isolation altogether. These kits allow pharmaceutical and research customers to run primary drug screens, exploratory toxicology studies, and large-scale biomarker discovery projects that were previously cost-prohibitive. The company is now commercializing the 1,536-well MERCURIUS DRUG-seq kit while also developing new RNA-seq technologies and proprietary transcriptomic data assets to support AI/ML research. Alithea’s solutions target the growing demand for “big RNA data,” aiming to be the foundational data engine for next-generation therapeutics. Recent leadership changes elevated Chairman Frederik Decouttere to CEO, enabling co-founder Riccardo Dainese to focus on market expansion as CCO. No revenue or user metrics were disclosed, but the fresh seed capital underpins the firm’s push toward broad commercialization and further R&D.

Participated · Seed · Sep 2023

BioLoomics develops a human-cell directed evolution platform to discover and engineer antibodies that drive target degradation and other spatial activities. The company combines synthetic biology, computer vision–guided cell picking, imaging, robotics, and machine learning to search antibody design space at high throughput. BioLoomics says its platform enables testing of antibody designs ~10,000x more than legacy methods and is adaptable across a wide variety of target classes. The team intends to use its technology to create safer, more effective cancer therapeutics by manipulating intracellular antibody trafficking. With the new capital, BioLoomics will advance proprietary platform technology and antibody degrader programs, develop pre-clinical assets, and pursue strategic partnerships with large pharma. The company is headquartered in Colorado and is actively recruiting for CSO and CTO roles; Dr. Nick Saccomano recently joined as an Independent Board Director.

Participated · Series A · Sep 2022

Naveris’ flagship product is NavDx, a blood test for early detection of cancers caused by human papillomavirus (HPV) that uses proprietary patented DNA fragmentomics to distinguish viral DNA arising from cancers versus infection. The company is commercial-stage and intends to use new proceeds to advance commercialization of NavDx and to generate clinical data needed to expand into other cancer types and indications. Naveris has partnered with more than 25 medical institutions to conduct clinical studies and trials using its technology and has collaborations with biotechnology companies developing immunotherapies for HPV-related cancers. Its clinical laboratory is CLIA-certified and accredited by the College of American Pathologists and the New York State Department of Health Wadsworth Center. The company was founded in 2017, maintains facilities in Massachusetts and North Carolina, and is led by founder and CEO Piyush B. Gupta, Ph.D. Naveris develops blood-based molecular diagnostic tests to detect viral-associated cancers, led by its NavDx® assay for HPV-related malignancies. NavDx® uses proprietary circulating tumor DNA genetic fingerprints derived from technology invented at the University of North Carolina Lineberger Cancer Center. The NavDx® test was clinically validated in a 3-year longitudinal study (published in the Journal of Clinical Oncology) showing 100% negative predictive value and 94% positive predictive value for detecting recurrence of HPV-related head and neck cancer. Naveris currently offers NavDx® through its CLIA laboratory to cancer centers across the U.S. The company plans to use new financing to expand patient access, generate data to support reimbursement and inclusion in treatment guidelines, and advance product development and its pipeline for other viral-related cancers. The company is led by Founder & CEO Piyush B. Gupta, PhD, with Philip Stephens, PhD as CSO and Barry Berger, MD as CMO.